- Home
- TCI vs MNPR Comparison
TCI vs MNPR Comparison
Compare TCI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCI | MNPR |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 368.9M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TCI | MNPR |
|---|---|---|
| Price | $34.70 | $56.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | 2.2K | ★ 150.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 54.99 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $49,060,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,761.50 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $31.48 | $28.40 |
| 52 Week High | $59.65 | $105.00 |
Technical Indicators
Market Signals| Indicator | TCI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 46.77 |
| Support Level | $35.00 | $56.15 |
| Resistance Level | $38.38 | $61.51 |
| Average True Range (ATR) | 0.76 | 4.81 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 26.40 | 36.01 |
Price Performance
Historical ComparisonAbout TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.